Creating
Strategic Partnerships Ecosystems
Turning health innovation into real-world impact through structured, validated and executable partnerships.
A Strategic Partnership Company with more than 23 years of experience operating at the intersection of health innovation, global markets and strategic alliances.
A UNIQUE KIND OF PARTNER
We are a Strategic Partnership Company. Not a consulting firm, not brokers, not an investment bank.
Our role is to help organizations design, validate, and activate partnership ecosystems that allow innovation to scale, portfolios to evolve and global expansion to happen with clarity and confidence.
Partnerships are not transactions. They are systems.
THE MOMENTUM GAP
Health innovation has never been more advanced, or more complex. Scientific progress, regulatory pressure, fragmented markets, capital constraints and global asymmetries make it increasingly difficult for any organization to move forward alone.
The challenge is not lack of opportunity. The challenge is momentum.
Strategic opportunities often exist but remain unrealized because organizations struggle to connect the right partners, under the right conditions, at the right moment.
Innovation increasingly requires capabilities that no single organization can fully internalize.
The solution is not to internalize more. The solution is to design and orchestrate the right ecosystem of partners.
WHAT THIS MEANS IN PRACTICE
Most organizations do not struggle because of lack of innovation. They struggle because strategic decisions must be made under uncertainty, across fragmented markets, regulatory complexity and constrained resources.
trifermed works on partnership-related challenges such as:
- designing international expansion strategies without overcommitting resources,
- building and prioritizing innovation portfolios,
- validating market and partner assumptions before execution,
- structuring partnerships that align long-term incentives.
Rather than addressing symptoms, trifermed focuses on the underlying strategic questions that determine whether partnerships will create momentum, or stall.
WHAT WE DO
trifermed helps health innovators, commercial organizations and investors transform strategic intent into executed partnerships. We do this by:
- designing partnership architectures,
- validating them in real market conditions,
- and supporting execution until aligned agreements are reached.
Our work spans biopharma, MedTech and digital health, across human and animal health, and across global markets.
Always with structure. Always with evidence. Always with alignment.
A SYSTEM, NOT A PROMISE
Over more than two decades, trifermed has translated its experience into a structured and replicable partnership system. It integrates:
- a proprietary methodology,
- real-world validation mechanisms,
- disciplined execution phases,
- and transparent partnership economics.
These economics are designed as part of the system, not as a commercial afterthought. This system is not shared publicly. It is introduced selectively, when there is mutual interest and strategic fit.
OUR SYSTEM
How trifermed turns strategic intent into executable partnerships
Over more than two decades of working across health innovation, trifermed has learned a simple but powerful lesson: most partnerships fail not because of lack of opportunity, but because of lack of structure, alignment and validation.
As complexity increased across markets, regulations, technologies and capital dynamics, ad-hoc approaches became insufficient. What was needed was not more analysis, but a disciplined way to make decisions and move forward under uncertainty.
A SYSTEM THAT GOES BEYOND A SINGLE METHODOLOGY
The trifermed Strategic Partnership System goes beyond a single methodology. At its core lies the Möbius Strategic Partnership Methodology, an iterative decision-making framework designed to align strategic intent with real-world validation.
Möbius guides how strategic hypotheses are designed, tested and refined, ensuring that partnership decisions are evidence-based rather than assumption-driven. This methodology is operationalized through a structured engagement model, typically articulated in three execution phases.
THREE INTEGRATED PILLARS
Strategic design
Every engagement starts by building a shared strategic foundation. This phase clarifies the business model, required capabilities and definition of success.
Market and partner validation
Strategic hypotheses are tested in real market conditions to reduce uncertainty and inform decisions.
Partnership structuring and execution
Validated opportunities are translated into aligned, executable partnership agreements.
MODULARITY AND OPTIONALITY
The system is modular and adaptive. Organizations can start focused, expand progressively, adjust direction based on evidence, or stop initiatives early when misalignment is identified. Stopping early is not failure; it is often one of the highest-value outcomes.
NOT PUBLIC BY DESIGN
The trifermed Strategic Partnership System is introduced only after an initial strategic conversation. This ensures it is always applied with the necessary context, depth and rigor. When introduced, the system is shared as a structured operational framework, including methodology, execution phases, decision logic and economic alignment, adapted to the specific context of each organization.
WHO WE WORK WITH
Designed for organizations that grow through partnerships
trifermed works with organizations that operate in complex health innovation environments and recognize that strategic partnerships are structural, not opportunistic. This is not about deal flow. It is about building the right ecosystem to move forward with clarity and confidence.
HEALTH INNOVATORS
For companies developing new technologies, products or platforms in health. This is for you if you value evidence over intuition and strategic discipline over speed. This is not for you if you expect fast deal-making without groundwork.
COMMERCIAL ORGANIZATIONS
For organizations expanding portfolios, geographies or strategic scope through external innovation. This is for you if you want to move from opportunistic sourcing to a structured partnership strategy. This is not for you if you prioritize transactional activity.
INVESTORS
For funds and investors seeking validated opportunities in health innovation. This is for you if you value real-world validation beyond pitch decks. This is not for you if you rely solely on financial models.
A SHARED MINDSET
Across all groups, trifermed works best with organizations that value strategic ambition, intellectual humility and long-term alignment. Partnerships only work when expectations, incentives and decision-making logic are aligned from the start.
CASE STUDIES
Strategic partnerships in real-world contexts
The value of a partnership system is demonstrated through real projects. The case studies presented here are selected examples, chosen to illustrate how strategic intent is translated into action across different contexts. They are not intended to be exhaustive, nor representative of the full breadth of work developed by trifermed over time. Additional case examples can be discussed and shared on demand, depending on context and relevance.
In many situations, trifermed operates under strict confidentiality agreements. As a result, a significant part of the work developed cannot be shared publicly. Respecting confidentiality is a mandatory and non-negotiable part of how trifermed works. These cases represent patterns of thinking and execution — not templates to replicate. This section is intentionally evolving and will be expanded progressively as new engagements mature.
Developer
Pioneering a first-in-class Phase II-ready novel topical treatment for Periodontitis
A U.S. dental research spin-off sought partners to finalize and commercialize its first-in-class topical treatment for periodontitis. By working with Trifermed to design and validate its business model, the company secured a co-development and licensing agreement covering the Nordics, Baltics, Iceland, and Russia, paving the way for Phase II readiness.
Valeo - Deployer
Strategic portfolio expansion & licensing partnership in the Parkinson’s treatment space
A Canadian specialty pharma company engaged Trifermed to expand its CNS portfolio. Through strategic asset scouting and partner negotiation, they secured exclusive rights to a novel Parkinson’s treatment from a European company. This licensing deal positioned them as a key player in the Canadian neurodegenerative disease market.
Cipher - Developer
Expanding dermatology and pain management products into Latin America
To expand into Latin America, a Canadian specialty pharma company partnered with Trifermed to launch an isotretinoin product in Brazil and extended-release tramadol in multiple countries. Trifermed facilitated strategic alliances with partners from India and Uruguay, enabling efficient market access and long-term collaboration across the region.
Mecwins-Quidel
Co-developing an ultra-sensitive diagnostic technology in the Point-of-Care space
Mecwins partnered with Trifermed to secure a global co-development and licensing agreement with Quidel. The collaboration leveraged Mecwins’ ultrasensitive AVAC technology and Quidel’s expertise in point-of-care diagnostics, enabling product development, regulatory advancement, and market validation in the IVD space.
Carnot
First sublingual immunotherapy sprays for respiratory and urinary infections in Mexico
Carnot partnered with Trifermed to identify and license innovative immunotherapies from Europe. Through Trifermed’s support, Carnot secured a deal with Inmunotek to launch Bactek® SL and Uromune® SL in Mexico—the first sublingual sprays to prevent respiratory and urinary infections—positioning Carnot as a leader in immunotherapy innovation.
Biologics Portfolio
Enabling access to global biosimilars in Brazil through strategic partnership
A Brazilian pharmaceutical company partnered with Trifermed to expand its biologics portfolio through strategic licensing. Trifermed facilitated a deal with a global biosimilar manufacturer, enabling regulatory and commercial entry into Brazil’s high-demand biologics market with differentiated, internationally registered therapies.
Undisclosed (Dermatology)
Expanding dermatology portfolio through a novel topical therapy for hyperhidrosis
A Mexican pharmaceutical company partnered with Trifermed to license a novel EU-approved topical treatment for severe primary axillary hyperhidrosis. This collaboration enabled exclusive commercialization in Mexico, Peru, and Colombia, reinforcing the company’s dermatology portfolio with a first-in-class solution and a strong regulatory launch strategy.